SCHEMBL5070512

SCHEMBL5070512

COc1ccccc1-c1nnc(-c2cc(C(F)(F)F)nn2-c2csc(CNC(=O)[C@H](C)NC(=O)OC(C)(C)C)c2)o1

nearest known ligand 0.60

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 10/20 0.60
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
PTGS2 P35354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5070510 1.00 CARM1 (0.60) CARM1CTSSCTSKPTGS2
SCHEMBL14012634 0.89 CARM1 (0.68) CARM1PTGS2
SCHEMBL4564381 0.88 CARM1 (0.77) CARM1
SCHEMBL4564380 0.88 CARM1 (0.77) CARM1
SCHEMBL5070507 0.86 CARM1 (0.53) CARM1CTSSCTSKPTGS2
SCHEMBL5070508 0.86 CARM1 (0.53) CARM1CTSSCTSKPTGS2
SCHEMBL5066928 0.81 CARM1 (0.41) CARM1
SCHEMBL5066927 0.81 CARM1 (0.41) CARM1
SCHEMBL4563439 0.81 ADORA3 (0.40) CARM1
SCHEMBL4563441 0.81 ADORA3 (0.40) CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280925-A1 Amines as Small Molecule Inhibitors CARM1, PRMT1, PRMT3 CARM1 1/4885CTSS 2744/4885CTSK 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.